Scinai Immunotherapeutics Ltd

Focused on developing, manufacturing and commercializing innovative inflammation and immunology (I&I) biological products | Previously BiondVax | Nasdaq: $SCNI

[Scinai Immunotherapeutics Ltd @scinai]

We are pleased to report our first quarter 2026 financial results!

Q1 2026 represented a tremendously important quarter for Scinai as we officially closed our #Acquistion of Recipharm Israel and Strategic #Collaboration with Recipharm. This allowed us to realize a tremendous increase not only in our total asset value but also in our total shareholder equity due to a gain from bargain purchase on the transaction of approximately $6.1M.

As we head into the 2H of 2026, Scinai is focused on scaling our CDMO platform, advancing pipeline programs toward key inflection points, and creating long-term shareholder value!

🔗 Link to the full earnings here! (https://t.co/XI4oCx71Iy)

#Biotech #BiotechInvesting #LifeSciences #SmallCap #GrowthStocks #CDMO #Immunology #Investors #SCNI

[Scinai Immunotherapeutics Ltd @scinai]

📣 Save the Date!

Scinai Immunotherapeutics is pleased to announce that our CEO, Amir Reichman, and Head of R&D, Meital Portugal, will be speaking at the 7th Annual Dermatology Drug Development Summit Europe taking place May 19–21, 2026 in Amsterdam, Netherlands.

The Scinai team will be speaking on a panel titled: “Fast-Tracking Transformative Access to Differentiated Drugs”.

We look forward to joining industry leaders and innovators to discuss the future of dermatology drug development and advancing differentiated therapies for patients in need!

📍 Amsterdam, NL
📅 May 19–21, 2026

#Scinai #Immunotherapy #Dermatology #DrugDevelopment #Biotech #Innovation #DDDSummitEurope

[Scinai Immunotherapeutics Ltd @scinai]

#NEWS This morning we announced a $2.61 million private placement financing led by institutional life sciences investor, with participation from new and existing investors.

This strategic capital is planned to support the expansion of our CDMO platform and advancement of customer programs.

You can view the full press release here: https://t.co/5sgkg3ZIlz

[Scinai Immunotherapeutics Ltd @scinai]

ICYMI: We DOUBLED our revenues!
For those of who didn’t have a chance to check out our earnings, watch the highlight clip below to hear the latest.

Not only did we double our revenues in 2025 vs the prior year, but we also significantly improved our cost structure and set up the company for a meaningful 2026, both in terms of expansion of our CDMO business as well as refining our R&D pipeline for our early-stage drug development.

Check out the clip to hear WHY we are tremendously excited for what’s to come in 2026!

[Scinai Immunotherapeutics Ltd @scinai]

Scinai looks like a company making a serious attempt to build a capital-efficient hybrid biotech model, with enough strategic movement to be interesting…”

We invite everyone to check out Pallavi Madhiraju’s article in PharmaDeviceNews covering our latest earnings report (FY 2025) and the excitement around how we are strategically re-shaping the Scinai platform to fully realize the potential of the revenue-generating CDMO platform, as well as our robust R&D pipeline built on multiple shots on goal.

We look forward to continuing to progress into 2026 and providing constant updates on the list of milestones we have planned for 2026. Thank you!

https://t.co/rbQCW8IiQO

#Scinai #Nasdaq #SCNI #CDMO #RevenueGrowth #biotechnology

[Scinai Immunotherapeutics Ltd @scinai]

Did you see our latest announcement?

Amir Reichman, Chief Executive Officer of Scinai, highlights what you need to know.

For the full press release, visit https://t.co/7g2jEki8Zd

[Scinai Immunotherapeutics Ltd @scinai]

https://t.co/7g2jEki8Zd

[Scinai Immunotherapeutics Ltd @scinai]

Today we announced the completion of a strategic reorganization at Scinai that reflects how we are evolving as a company.

Over the past year, we have taken significant steps to build a differentiated CDMO platform alongside our R&D activities, including the acquisition of Recipharm Israel and our collaboration with Recipharm.

With this reorganization, we have now formally consolidated all CDMO activities under Scinai Biopharma Services Ltd., our wholly owned subsidiary, while establishing Scinai Immunotherapeutics as a lean, focused R&D organization.

This structure is designed with a clear objective:

- On the CDMO side: to operate as a focused, customer-facing platform with scalable capabilities across biologics and small molecules, supported by access to Recipharm’s global network

- On the R&D side: to operate as a capital-efficient biotech focused on advancing high-value programs and engaging with partners and investors

We believe this structure strengthens our ability to create and capture value across both parts of the business, while positioning us for future growth and strategic opportunities!

Link to the full press release is in the comments.

[Scinai Immunotherapeutics Ltd @scinai]

Strong momentum for @scinai, heading to BIO-Europe Spring 2026 🇵🇹Expanding CDMO capabilities following the Recipharm Israel acquisition + strategic global collaboration with @RecipharmAB, while advancing its immunology pipeline in parallel.📍 Booth #24#BIOEuropeSpring
https://t.co/vfd6VHPu6x
$SCNI #CDMO #Biotech #Immunotherapy

[Scinai Immunotherapeutics Ltd @scinai]

Today we announced the execution of an updated amendment to the binding option agreement for the #Acquisition of PinCell S.r.l., and the submission of a revised application under the European Funds for the Modern Economy (FENG) SMART Path program.

The Company's revised application seeks €12 million in non-dilutive, non-repayable funding to support a €15 million integrated R&D program for PC111 a fully human monoclonal antibody targeting soluble Fas Ligand (sFasL) for the treatment of pemphigus vulgaris (PV) and Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN), representing 80% project co-financing.

The Company expects a funding decision within approximately three to four months following submission.

Read more: https://t.co/Q4E8c4E1nn

#Scinai #Pincell #ResearchandDevelopment #Partnership #Biotech #FENG #NonDilutive

[Scinai Immunotherapeutics Ltd @scinai]

In Case You Missed It - A Major Step Forward for Scinai!

Last week, we announced a transformative agreement with Recipharm - and it marks an exciting new chapter for Scinai.

The transaction brings together infrastructure, capital support, and a commercial partnership designed to accelerate our CDMO strategy while strengthening our financial foundation.

In a challenging biotech environment, this deal:
✔️ Adds immediate operational capabilities
✔️ Provides meaningful runway
✔️ Aligns us with a global CDMO leader
✔️ Creates a platform for scalable growth
In the video below, Amir shares why this transaction is such a powerful move for Scinai right now - and what it unlocks for the future.
Don’t miss it.
#Scinai #Recipharm #StrategicTransaction #CorporateUpdate #CDMO #LifeSciences #PharmaServices #DrugDevelopment #Biomanufacturing

[Scinai Immunotherapeutics Ltd @scinai]

Welcoming the @RecipharmAB Israel team into @scinai - discussing exciting new growth opportunities ahead. 🚀$SCNI #StrongerTogether #GrowthJourney #NewBeginnings @ReichmanAmir

[Scinai Immunotherapeutics Ltd @scinai]

#NEWS: We have officially announced the completion of our #Acquisition of Recipharm Israel Ltd. and strategic commercial collaboration with Recipharm. This milestone marks a tremendously important step forward for $SCNI manufacturing footprint, capabilities, and commercial positioning, strengthening our CDMO platform and creating a differentiated, end-to-end development and manufacturing offering spanning early development directly by Scinai and late-stage clinical and commercial supply by Recipharm.

Read more: https://t.co/uK8x4pllpN

#Scinai #Recipharm #CDMO #Partnership #Biotech #ClinicalManufacturing

[Scinai Immunotherapeutics Ltd @scinai]

Highlighting the below piece by our CEO, Amir Reichman, where he offers his perspective and insights on the VHH antibody space and that while these antibodies are not a "new technology", what matters more than ever in the current environment is the differentiation, clinical context, and execution discipline required within development.

It is clear there is a renewed interest in this modality, and we at Scinai are excited to be at the forefront of innovation!

https://t.co/ppizL3hDGq

[Scinai Immunotherapeutics Ltd @scinai]

ICYMI: Scinai reported our Q3 earnings results last week!

• Revenue more than doubled YoY driven by CDMO growth

• Non-dilutive funding secured to expand manufacturing

• Disciplined R&D with focus on NanoAbs pipeline

• Positioned for key 2026 milestones

🔗 Full release: https://t.co/hbpvDBnR1F

#Biotech #BiotechInvesting #LifeSciences #SmallCap #GrowthStocks #CDMO #Immunology #Investors #SCNI

[Scinai Immunotherapeutics Ltd @scinai]

Scinai CEO, Amir Reichman , is proud to represent Scinai Immunotherapeutics this week as part of the Rhineland-Palatinate Biotech Delegation in Germany!

The delegation is meeting leading institutions - including the Biotechnology Campus Mainz, BioVation RLP, biomindz – Life Science Hub Mainz, UniMed Mainz, Midas Pharma , and Boehringer Ingelheim - to deepen collaboration between Israel and one of Europe’s most vibrant life-science regions.

Amir is highlighting Scinai’s work developing novel I&I biologics and expanding our boutique CDMO capabilities, while connecting with partners across the German innovation ecosystem.

This is a great opportunity to strengthen ties, explore new partnerships, and showcase the impact of Scinai’s science and services!

#Scinai #Biotech #Innovation #Germany #Israel #LifeSciences #CDMO

[Scinai Immunotherapeutics Ltd @scinai]

https://t.co/6WvKl83CNE

[Scinai Immunotherapeutics Ltd @scinai]

Scinai Q3 Earnings — Momentum Building Continues

We are pleased to share the latest results from Scinai: our CDMO business is gaining real traction, and we’ve made meaningful progress on strengthening our financial footing and I&I pipeline!

Key highlights:

📈 CDMO revenue growth continues to outpace expectations, reflecting increasing demand for our biologics manufacturing and development services.

💡 We’re executing on our dual–engine strategy: scaling CDMO services while advancing our proprietary R&D pipeline of nanoAbs for inflammation & immunology (I&I).

👇 On the balance-sheet and cash-flow side: we significantly improved liquidity, reduced net loss compared to prior period, and further de-risked operations via strategic funding.

✅ Taken together — these results underscore that Scinai is no longer just a biotech in waiting. We are executing on a sustainable, dual-track model that combines external-facing manufacturing services with internally developed therapeutics.

Thank you to all colleagues, partners, and investors for the continued trust. We look forward to what’s ahead in the next phase of growth!

(Link to PR in the comments)

#Biotech #CDMO #Immunotherapeutics #Nanobodies #Investing #Scinai #SC

[Scinai Immunotherapeutics Ltd @scinai]

Industry Insight: Why “Good Data” Sometimes Isn’t Good Enough

Recent Phase 3 readouts in the inflammation and immunology (I&I) space have shown that even statistically positive results may not be enough. Investors and prescribers are increasingly demanding meaningful differentiation: new therapies must not only work but deliver real-world value for patients, physicians, and payers.

At Scinai Immunotherapeutics, we’re addressing this challenge with a first-in-class intradermal nanobody platform designed to deliver biologics locally, directly to the site of inflammation, rather than systemically throughout the body.

Our lead psoriasis program targets patients underserved by current options, including:

Mild-to-moderate patients who wish to avoid chronic topical corticosteroid use due to side effects such as skin atrophy.

Patients using advanced topicals (e.g., ZorivE™, Vtama®) who struggle with daily application and adherence.

Phototherapy patients who must attend frequent outpatient sessions for weeks at a time.

Patients with lesions in sensitive areas (face, scalp, genitals, palms, soles) who may currently receive systemic biologics due to the psychosocial burden of their disease, even though their overall disease severity is limited.

Our intradermal administration is performed using a mesogun, a device already well established in dermatology for applications such as hair restoration and skin rejuvenation. This approach enables precise, virtually painless delivery of nanobody-based biologics directly into the affected skin.

By providing a localized, safer, and more convenient alternative to systemic biologics, our technology addresses a key unmet need: offering biologic-level efficacy appropriate to the patient’s disease severity while reducing systemic exposure, improving adherence, and lowering overall treatment costs.

As the field seeks innovation that goes beyond incremental efficacy improvements, Scinai’s localized nanobody platform offers a de-risked, differentiated path to redefining care for inflammatory skin diseases.

👉 Learn more at https://t.co/ZN9wENMH2v